Pharmaceutical composition for treating acute lung injury

A technology of acute lung injury and composition, applied in the field of biopharmaceuticals, can solve the problems of inability to fundamentally treat acute lung injury, poor treatment effect, and treat the symptoms but not the root cause, so as to treat acute lung injury, reduce the degree of edema, and reduce the cost. cheap effect

Inactive Publication Date: 2017-07-07
HENAN UNIV OF SCI & TECH
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to provide a pharmaceutical composition for the treatment of acute lung injury, to solve the problem that the current drug treatment for acute lung injury proposed in the above-mentioned background technology has a poor therapeutic effect, and there is a problem of treating the symptoms but not the root cause. Treatment of acute lung injury, and the problem of long treatment time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] A pharmaceutical composition for treating acute lung injury, the main components of the pharmaceutical composition for treating acute lung injury include:

[0022] Puerarin: 20 parts, the puerarin adopts puerarin as a raw material, extracts with n-butanol as a solvent, concentrates the extract and reclaims n-butanol to obtain a paste, which is obtained by crystallization of the paste;

[0023] Verapamil: 0.3 parts, the verapamil is verapamil hydrochloride, and its molecular weight is 491.07;

[0024] Ulinastatin: 1 part, the ulinastatin is a white or slightly yellow freeze-dried block or powder, which is composed of 143 amino acids and has a relative molecular mass of 67,000;

[0025] NE inhibitor: 0.8 parts, the NE inhibitor is one or more combinations of ONO-6818, EPI-HNE-4 or Sc-39026;

[0026] Salvia miltiorrhiza water extract: 0.5 parts, the salvia miltiorrhiza water extract is prepared by mixing salvia miltiorrhiza and deionized water, decocting, filtering and co...

Embodiment 2

[0029] A pharmaceutical composition for treating acute lung injury, the main components of the pharmaceutical composition for treating acute lung injury include:

[0030] Puerarin: 24 parts, the puerarin adopts kudzu root as a raw material, extracts with n-butanol as a solvent, concentrates the extract and reclaims n-butanol to obtain a paste, which is crystallized;

[0031] Verapamil: 0.4 parts, the verapamil is verapamil hydrochloride, and its molecular weight is 491.07;

[0032] Ulinastatin: 1.5 parts, the ulinastatin is a white or slightly yellow freeze-dried block or powder, which is composed of 143 amino acids and has a relative molecular mass of 67,000;

[0033] NE inhibitor: 0.8 parts, the NE inhibitor is one or more combinations of ONO-6818, EPI-HNE-4 or Sc-39026;

[0034] Salvia miltiorrhiza water extract: 0.3 parts, the salvia miltiorrhiza water extract is prepared by mixing salvia miltiorrhiza and deionized water, decocting, filtering and collecting the filtrate i...

Embodiment 3

[0037] A pharmaceutical composition for treating acute lung injury, the main components of the pharmaceutical composition for treating acute lung injury include:

[0038] Puerarin: 23 parts, the puerarin adopts puerarin as a raw material, extracts with n-butanol as a solvent, concentrates the extract and reclaims n-butanol to obtain a paste, which is obtained by crystallization of the paste;

[0039] Verapamil: 0.3 parts, the verapamil is verapamil hydrochloride, and its molecular weight is 491.07;

[0040] Ulinastatin: 1.5 parts, the ulinastatin is a white or slightly yellow freeze-dried block or powder, which is composed of 143 amino acids and has a relative molecular mass of 67,000;

[0041] NE inhibitor: 0.7 parts, the NE inhibitor is one or more combinations of ONO-6818, EPI-HNE-4 or Sc-39026;

[0042] Salvia miltiorrhiza water extract: 0.4 parts, the salvia miltiorrhiza water extract is prepared by mixing salvia miltiorrhiza and deionized water, decocting, filtering and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating acute lung injury and belongs to the technical field of biopharmaceutical industry. The pharmaceutical composition comprises the following main components in parts by weight: 20-25 parts of puerarin, 0.2-0.4 part of verapamil, 1-2 parts of ulinastatin, 0.6-0.8 part of an NE inhibitor, 0.3-0.6 part of a salviae miltiorrhizae water extract and 0.4-0.8 part of glutamine. The invention provides the pharmaceutical composition for treating acute lung injury. By means of matched use of puerarin and verapamil, the pharmaceutical composition can effectively treat acute lung injury and inhibit rise of content of blood serum TNF-alpha, alleviate PMN infiltration, eliminate free radicals and alleviate the extent of lung tissue edema, and has an effective protecting action on acute lung injury; and moreover, the oxygenation index of arterial partial pressure of oxygen is obviously increased, and the respiratory function of a patient is improved. The pharmaceutical composition disclosed by the invention not only can treat acute lung injury effectively, but also plays a maintaining role on lungs, and is convenient to use and low in cost.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to a pharmaceutical composition for treating acute lung injury. Background technique [0002] Acute lung injury (Acute lung injury, ALI) is caused by a variety of reasons, based on diffuse lung cell damage, characteristic pathological changes in lung tissue structure, pulmonary edema and pulmonary atelectasis as pathological features, rapidly affecting gas Exchange function is the clinical hallmark of pulmonary inflammation and increased permeability syndrome. Its pathological features are alveolar capillary endothelial cells and alveolar epithelial cell damage, manifested as extensive pulmonary edema and tiny atelectasis. The pathophysiological changes are mainly increased intrapulmonary shunt and decreased lung compliance. Clinically, hypoxemia, rapid respiratory rate, and diffuse infiltration of both lungs appeared on chest X-ray. [0003] The etiology of acute lung...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K38/57A61K36/537A61K31/352A61K31/277A61K31/198A61P11/00
CPCA61K45/06A61K31/198A61K31/277A61K31/352A61K36/537A61K38/57A61K2300/00
Inventor 安君岭安计江杨晖王梅林王萍
Owner HENAN UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap